Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Benign Prostatic Hyperplasia Treatment Market Size And Revenue Outlook Through 2030
The benign prostatic hyperplasia treatment market has experienced significant growth in recent years. It is projected to expand from $8.69 billion in 2025 to $9.17 billion in 2026, with a compound annual growth rate (CAGR) of 5.6%. The historical growth in this market is attributable to factors such as an increasing aging male population, a rising prevalence of urinary disorders, the expansion of urology specialty services, a growing use of pharmacological treatments, and improved access to diagnostic screening.
The benign prostatic hyperplasia treatment market is projected to experience robust expansion over the coming years. This market is anticipated to reach $11.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. Factors driving this growth during the forecast period include the increased uptake of robotic-assisted prostate procedures, a heightened emphasis on personalized treatment planning, the broadening of home-based therapy options, the growing incorporation of digital patient monitoring tools, and an escalating demand for minimally invasive interventions. Key trends anticipated for this period encompass a greater embrace of minimally invasive surgical techniques, a surging demand for targeted drug therapies, an increasing application of combination treatment approaches, the expansion of outpatient treatment environments, and an improved focus on managing symptoms and enhancing quality of life.
Get A Free Sample Report With In-Depth Market Insights:
Benign Prostatic Hyperplasia Treatment Market Development Factors: What’s Supporting Demand?
The increasing acceptance of minimally invasive surgeries is anticipated to drive the expansion of the benign prostatic hyperplasia treatment market in the coming years. Minimally invasive surgeries are procedures characterized by small or no incisions, employing specialized instruments to lessen recovery periods, discomfort, and potential complications. The growing embrace of these surgeries is fueled by advantages such as quicker recovery times, reduced pain, lower risk of complications, and improved cosmetic outcomes. When applied to benign prostatic hyperplasia treatment, minimally invasive procedures offer patients shorter recovery times, fewer risks of complications, and effective symptom relief, thereby enhancing overall surgical success. For instance, in September 2023, according to the American Society of Plastic Surgeons (ASPS), a U.S.-based professional association, nearly 25.4 million minimally invasive cosmetic procedures were performed in 2023, a rise of 7% from 23.7 million in 2022. Thus, the increased adoption of minimally invasive surgeries is a significant factor propelling the growth of the benign prostatic hyperplasia treatment market.
Benign Prostatic Hyperplasia Treatment Market Segment Analysis Spotlighting Growth Areas
The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Benign Prostatic Hyperplasia Treatment Market Transformation Trends: What Innovations Are Driving Change?
Leading firms within the benign prostatic hyperplasia treatment market are concentrating on creating cutting-edge therapies, like intraprostatic drug elution, to secure a competitive edge. This method entails inserting a bioabsorbable device directly into the prostate gland for the sustained, localized release of a therapeutic compound. An example of this is Resurge Therapeutics, a US-based urology technology developer, which launched a paclitaxel-eluting bioabsorbable implant for BPH in May 2025; this innovation allows for administration in a clinical setting, precise drug targeting, and reduced discomfort following the procedure. Such a localized approach minimizes systemic absorption, boosts effectiveness, and helps maintain sexual health. Nevertheless, its long-term safety and widespread implementation are still undergoing assessment.
Benign Prostatic Hyperplasia Treatment Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.
View The Full Benign Prostatic Hyperplasia Treatment Market Report:
Benign Prostatic Hyperplasia Treatment Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









